Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FXII-uPAR-abrogating peptide combination
- Development stage
- Preclinical
- Lead developer
- Case Western Reserve University
- Modality
- Peptides
- Administration
- Intraperitoneal, Intravenous, Subcutaneous
01
Overview
The FXII-uPAR-abrogating peptide combination is a therapeutic mixture of synthetic peptides designed to disrupt the interaction between coagulation factor XII (FXII) and the urokinase-type plasminogen activator receptor (uPAR). This interaction, which occurs independently of FXII's enzymatic protease activity, acts as an autocrine signaling axis in neutrophils and other cells, promoting Akt2 phosphorylation, neutrophil activation, and trafficking to sites of sterile inflammation. By blocking the FXII-uPAR axis, this peptide combination suppresses neutrophil-mediated sterile inflammation, reduces the accumulation of malignant ascites, and decreases tumor burden and metastasis in epithelial ovarian cancer. It also shows therapeutic potential in deep vein thrombosis, chronic wound healing, and sickle cell disease.
- Other names
- ComboFXII-uPAR-abrogating peptidesFactor XII binding peptidesuPAR-binding peptides
02
Targets
AKT2 (Rac-beta serine/threonine-protein kinase)F12 (Coagulation Factor XII)EGFR (Epidermal growth factor receptor)MAPK3 (Mitogen-activated protein kinase 1)KNG1 (High-molecular-weight kininogen)ITGB1 (Integrin beta-1)PLAUR (Urokinase plasminogen activator receptor)
Beyond the preview
Go deeper on FXII-uPAR-abrogating peptide combination.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FXII-uPAR-abrogating peptide combination.